ClinicalTrials.gg
TerminatedNCT04791514Updated Sep 22, 2023Results posted

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of Treprostinil Palmitil in Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-22.

Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment

Why this study was terminated
Low enrolment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
237th of 253
1 · median 40
Started
2022
with 11 others
Phase 2
82 of 312
11 open now
Registered
240th of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 237th largest by enrollment of the 253 interventional ones that give a count, is one of 12 that started in 2022, is one of 82 in phase 2, and was the 240th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of single dose of treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial hypertension (PAH).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary Arterial Hypertension
  • Treprostinil Palmitil Inhalation Powder
  • Treprostinil Palmitil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age at the time of signing the
  • Participants must have a diagnosis of World Health Organization Group 1 Pulmonary Hypertension (PH) (PAH) with the following characteristics

    1. Etiology of idiopathic, heritable, drug/toxin-induced or connective tissue disease (CTD)-related PAH
    2. Right heart catheterization with the following hemodynamic findings:
  • Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest,
  • Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and
  • Pulmonary vascular resistance (PVR) of ≥ 3 Wood Units (WU)
  • No change in pulmonary hypertension medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 90 days prior to Screening
  • No change in diuretic use or dosage for at least 30 days prior to Screening
  • (BMI) within the range 18.0 - 32.0 kg/m\^2 (inclusive)
  • Male participants: Male participants and their female partners of must agree to use highly effective from Study Day 1 to at least 90 days after dosing
  • Female participants: Women of child-bearing potential (WOCPB, defined as premenopausal, not surgically sterile for at least 3 months prior to Screening) must use a highly effective contraception method and agree to be tested for pregnancy from at Screening, Baseline, and 30 days after dosing
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Any PH other than idiopathic, hereditary, drug/toxin-induced, or connective tissue disease (CTD) associated PAH (eg, congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5)
  • Allergy, or documented or , to the ingredients of treprostinil palmitil inhalation powder (TPIP) or treprostinil (TRE)
  • Previous intolerance to prostacyclin analogs or receptor agonists (eg, selexipag) per investigator discretion
  • History of anaphylaxis or previously documented hypersensitivity reaction to any drug per Investigator discretion
  • History of heart disease including (LVEF) ≤ 40% or valvular, constrictive, or atherosclerotic heart disease (myocardial infarction, etc)
  • Active liver disease or hepatic dysfunction manifested as:

    1. Elevated liver function test results ( or AST > 2 × ) at Screening
    2. > 1.5 × ULN (isolated bilirubin > 1.5 × ULN; ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%) at Screening.
    3. Known hepatic or biliary abnormalities, not including Gilbert's syndrome or asymptomatic gallstones at Screening.
  • History of infection/positive HIV serology test result at Screening
  • History of active/chronic or C/ positive hepatitis B or C serology test result at Screening
  • History of abnormal bleeding or bruising
  • Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immune-compromised status, as judged by the investigator
  • Active and current symptomatic infection by SARS CoV 2
  • Participants with current or recent (past 4 weeks) lower respiratory tract infection
  • History of in the past 5 years, with exception of completely treated in situ carcinoma of the cervix and completely treated non- squamous or basal cell carcinoma of the skin
  • Participants receiving triple combination therapy for PAH consisting of endothelin receptor agonists, phosphoesterase type 5 inhibitors, and guanylate cyclase stimulators (riociguat)
  • Participants receiving prostanoids/prostacyclin agonists
  • Participants receiving potent CYP2C8 inhibitors, such as gemfibrozil
  • Have participated in any other interventional clinical studies within 30 days of Baseline
  • Current or history of substance and/or alcohol abuse
  • Current user of cigarettes or e-cigarettes
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Treprostinil Palmitil Inhalation Powder

    Participant received a single dose of TPIP 112.5 micrograms (μg) via oral inhalation on Day 1. The participant then entered into a 16-week Extended Use Treatment (EUT) Period during which TPIP, administered via oral inhalation, was titrated up to a mean daily dose of 320 μg.

    Drug: Treprostinil Palmitil

Interventions

  • Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler

    Also known as: INS1009

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)

    Time frame: Up to 150 days

Secondary outcomes

  1. Change From Baseline in Pulmonary Vascular Resistance (PVR) After TPIP Administration

    Time frame: Day 1: Pre-treatment (Baseline), 8 and 24 hours post-treatment

  2. Maximum Observed Concentration (Cmax) of Treprostinil (TRE) in Plasma

    Time frame: Pre-dose and multiple timepoints post-dose up to Day 2

  3. Time to Maximum Concentration (Tmax) of Treprostinil (TRE) in Plasma

    Time frame: Pre-dose and multiple timepoints post-dose up to Day 2

  4. Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of Treprostinil (TRE) in Plasma

    Time frame: Pre-dose and multiple timepoints post-dose up to Day 2

  5. Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Treprostinil (TRE) in Pasma

    Time frame: Pre-dose and multiple timepoints post-dose up to Day 2

  6. Elimination Half-life (t1/2) of Treprostinil (TRE) in Plasma

    Time frame: Pre-dose and multiple timepoints post-dose up to Day 2

07

Results

Posted Sep 22, 2023
Limitations and caveats
The study was terminated by the Sponsor due to low enrolment. As only 1 participant was enrolled in this study, no data is reported here, in order to protect and maintain participant privacy/confidentiality.

Participant flow

The study was terminated by the Sponsor due to low enrolment. As only 1 participant was enrolled in this study, no data is reported here, in order to protect and maintain participant privacy/confidentiality.

Participant flow — Overall Study
MilestoneTreprostinil Palmitil Inhalation Powder (TPIP)
Started0
Completed0
Not completed0

Outcome measures

PrimaryNumber of Participants Who Experience a Treatment Emergent Adverse Event (TEAE)
Time frame:
Up to 150 days

No measurements were reported for this outcome.

SecondaryChange From Baseline in Pulmonary Vascular Resistance (PVR) After TPIP Administration
Time frame:
Day 1: Pre-treatment (Baseline), 8 and 24 hours post-treatment

No measurements were reported for this outcome.

SecondaryMaximum Observed Concentration (Cmax) of Treprostinil (TRE) in Plasma
Time frame:
Pre-dose and multiple timepoints post-dose up to Day 2

No measurements were reported for this outcome.

SecondaryTime to Maximum Concentration (Tmax) of Treprostinil (TRE) in Plasma
Time frame:
Pre-dose and multiple timepoints post-dose up to Day 2

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of Treprostinil (TRE) in Plasma
Time frame:
Pre-dose and multiple timepoints post-dose up to Day 2

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Treprostinil (TRE) in Pasma
Time frame:
Pre-dose and multiple timepoints post-dose up to Day 2

No measurements were reported for this outcome.

SecondaryElimination Half-life (t1/2) of Treprostinil (TRE) in Plasma
Time frame:
Pre-dose and multiple timepoints post-dose up to Day 2

No measurements were reported for this outcome.

Adverse events

Collected over Up to 150 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treprostinil Palmitil Inhalation Powder (TPIP)———

Baseline characteristics

The study was terminated by the Sponsor due to low enrolment. As only 1 participant was enrolled in this study, no data is reported here, in order to protect and maintain participant privacy/confidentiality.

Age, Continuous
Age, Continuous(years)Treprostinil Palmitil Inhalation Powder (TPIP)
Sex/Gender, Customized
Sex/Gender, CustomizedTreprostinil Palmitil Inhalation Powder (TPIP)
Race/Ethnicity, Customized
Race/Ethnicity, CustomizedTreprostinil Palmitil Inhalation Powder (TPIP)
Race/Ethnicity, Customized
Race/Ethnicity, CustomizedTreprostinil Palmitil Inhalation Powder (TPIP)
08

Study locations

1 site
  • USA002
    New York, New York 10021-9800, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Aug 2022, 4 months.

Results were first posted in Sep 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2021
First posted
Mar 10, 2021
StartActual
Mar 29, 2022
Primary completionActual
Aug 26, 2022
CompletionActual
Aug 26, 2022
Results first posted
Sep 22, 2023
Last update
Sep 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04791514
Responsible party
Sponsor
First posted
Mar 10, 2021
Start date
Mar 29, 2022
Primary completion
Aug 26, 2022
Completion
Aug 26, 2022
Results posted
Sep 22, 2023
Last update
Sep 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil hexadecyl ester

Start the discussion